Therapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer

Xanthohumol suppresses oestrogen-signalling in breast cancer through the inhibition of BIG3-PHB2 interactions

(2014) Tetsuro Yoshimaru et al.   Scientific Reports

Prohibitin Ligands in Cell Death and Survival: Mode of Action and Therapeutic Potential

(2013) Frédéric Thuaud et al.   CHEMISTRY & BIOLOGY

Targeting BIG3–PHB2 interaction to overcome tamoxifen resistance in breast cancer cells

(2013) Tetsuro Yoshimaru et al.   Nature Communications

PKA phosphorylation redirects ERα to promoters of a unique gene set to induce tamoxifen resistance

(2012) R de Leeuw et al.   ONCOGENE

Estrogen Receptor-  Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer

(2010) J. Bostner et al.   CLINICAL CANCER RESEARCH

Clinical significance of estrogen receptor phosphorylation

(2010) L. C. Murphy et al.   ENDOCRINE-RELATED CANCER

Activation of an estrogen/estrogen receptor signaling by BIG3 through its inhibitory effect on nuclear transport of PHB2/REA in breast cancer

(2009) Jung-Won Kim et al.   CANCER SCIENCE

Preclinical modeling of endocrine response and resistance

(2007) Luciana F. Macedo et al.   CANCER